Recherche de nouveaux gènes impliqués dans la tumorigenèse mammaire par analyses « Omiques »

The high heterogeneity of clinical, histological, biological and genetic features in breast cancer is due in part to the extreme molecular complexity of these tumors. This review article presents the major technological advances of the past ten years, in particular the development of microarray approaches, which have enabled genome-wide (“Omics”) analysis of these tumors. Numerous genetic and epigenetic alterations involving a small number of altered signalling pathways (PI3K, NK-κB, FGF, etc.) have been described. The next decade will be even more prolific in terms of discovery with the advent of next-generation sequencing (NGS) technologies that will provide fast and low cost constitutional and somatic genome sequences. The full catalogue of somatic genetic alterations will result in a completely new individual management for breast cancer patients.